GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Silo Pharma SILO · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.63

+22.56%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Silo Pharma

From its filings with the US Securities and Exchange Commission

SEC filings

Silo Pharma is based in Sarasota, Florida and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker SILO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $72,102 and a net loss of $4.2m. At that date it held total assets of $7.6m and shareholders' equity of $6.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
5 Jan 2012
Head office
677 N. WASHINGTON BLVD, SARASOTA, FL, 34236
Incorporated in
NV
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Eric WeisblumChairman of the Board, President, Chief Executive Officer, since 2013$569,009
  • Mr. Daniel RyweckChief Financial Officer$62,692
  • Mr. Wayne LinsleyIndependent Director$45,000
  • Dr. Kevin MunozIndependent Director$25,000
  • Dr. Jeff PavellIndependent Director$25,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Silo Pharma focuses on merging traditional therapeutics with psychedelic research for PTSD and Alzheimer's treatment.
  • The company has a sponsored research agreement with Columbia University for Alzheimer's and stress disorder treatments.
  • Silo Pharma's business model includes acquiring intellectual property from universities to develop rare disease therapies.

Weaknesses

  • The company is a developmental stage biopharmaceutical firm with no commercial products yet.
  • Silo Pharma's IPO was in 2012, indicating a long development timeline for its therapies.
  • The firm's focus on psychedelic drugs may face regulatory challenges in the US market.

Opportunities

  • Silo Pharma can expand its research into psychedelic treatments for depression and mental health issues.
  • The company may benefit from growing interest in psychedelic-assisted therapy for neurological disorders.
  • Columbia University's research could lead to new patent licenses for rare disease treatments.

Threats

  • Regulatory hurdles for psychedelic drug approvals in the United States pose a significant risk.
  • The developmental stage of Silo Pharma's therapies may delay market entry and revenue generation.
  • Competition in the biotechnology sector for rare disease treatments is increasing.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.